about
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.The tumor lysis syndromeTreating childhood acute lymphoblastic leukemia without cranial irradiationGenes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocolsToward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge.Global Pediatric Oncology: Lessons From Partnerships Between High-Income Countries and Low- to Mid-Income CountriesSecond malignant neoplasms and cardiovascular disease following radiotherapy.Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexateGenetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemiaModeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cellsGermline genomic variants associated with childhood acute lymphoblastic leukemiaGenome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemiaGenome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemiaNovel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populationsHLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Feasibility and initial effectiveness of home exercise during maintenance therapy for childhood acute lymphoblastic leukemiaImplementation of a data management program in a pediatric cancer unit in a low income country.Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia.Quantitative morphologic evaluation of magnetic resonance imaging during and after treatment of childhood leukemia.Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPsComponents of cure: treatment of acute lymphoblastic leukemia in Indonesia and other low-income countries.Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamicsIntrathecal liposomal cytarabine: more friend than foe?Conservative management of pancreatic pseudocysts in children with acute lymphoblastic leukemiaManagement of occlusion and thrombosis associated with long-term indwelling central venous catheters.High-risk childhood acute lymphoblastic leukemiaInherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemiaPG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing.Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia.Attention and working memory abilities in children treated for acute lymphoblastic leukemia.Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
P50
Q24601515-5AC7DDE2-DCBC-4E47-B09C-EE32AC95CE3BQ24605151-908710C2-7DC0-4FC5-B4AA-3C0B5BF72A88Q24644599-AC0B96A2-FEA6-49E8-BA45-7AAF4CC26922Q24685514-9032F38D-20C2-4AD4-B073-14DADF2E7507Q24685883-B4DF688C-5AA3-4642-B6FF-167933D24078Q26797524-19B264F7-0222-42CE-AD22-A4F0EA4F1FCCQ26829304-BBD409E3-FD8E-4966-8A34-C89BFD05A3ACQ26864522-944B917F-C01A-4943-960B-6CC474BDAD02Q28250460-53F09FCA-2184-4625-BF82-0102986AA3A8Q28280878-078ED4F5-BE03-46CC-8943-538DBAFD73B0Q28476416-1AC286C5-516C-4741-8C80-26123E61F157Q28924384-0866A42D-D5BE-42B9-8B0A-989D594C676BQ28943308-1E26F60B-7666-4666-B2F5-F897D61886BAQ28943431-AF692DBA-286B-4114-8C1E-34915E52C306Q28943485-68E6AE95-B1BF-4CB3-849E-9E758C9EBA0AQ30371340-19572697-5F91-4ED9-8C2D-CBB385523DA6Q30596383-83CB36AB-FE06-4A27-9FE6-F567CBEC01F3Q31049576-67237501-9F1E-4771-A457-4AFD489D49E9Q31103489-674AA4E4-854F-42A2-9CCE-F77799AE6FE1Q33291796-2F8B6A13-F356-4819-96D1-51C2059AB5E6Q33334373-0A58D161-CBB0-4177-9E13-0229F3409B29Q33371889-1E9B8CB9-4D3C-4614-B726-45EB4AF3E6C0Q33423823-AF395AF4-D548-46AA-A1C4-6E56DB29A79BQ33565612-B66B64AA-5CB1-44E2-B076-12DC84270372Q33577149-307A2683-010D-40FC-AC9A-B6B651826172Q33611308-D70AE3F0-0208-4B63-A0AA-586C773C1D1DQ33622659-2CF8CA39-FFFC-468C-A737-BA2377B52731Q33622837-E644E91F-E585-4F2B-B5AC-34E5925D28CBQ33688248-6979AE6B-2F86-4E82-A5CC-9C5AAC3C3ACBQ33710760-2AACD040-ADB4-4E34-A035-E56F2B95FF87Q33733461-6B8D9530-F144-44BD-9DD4-64110040EA0AQ33751939-C45FF0ED-6795-41B9-A750-ABE40835FFCFQ33758537-CC122EDA-6C4B-4CFF-A79E-F8252762B779Q33762835-76B7D8A4-CC71-48C6-8201-8E84798189A4Q33779342-A5660551-5D55-46CB-A9FA-223EB07BA88EQ33880838-559D389F-E45D-4EAB-A05A-0935231790DBQ33931882-15891E8C-4F29-48A4-BAE0-6E12CC3BF4F6Q34096751-FE1BBDFE-C6C8-4125-8798-B0BFA5E94260Q34159130-3A5AA6CD-BCF9-4620-87AF-44C75250CAD3Q34172033-AEDF3552-6A6F-4FF5-83D6-10FDE5A04D34
P50
name
Ching-Hon Pui
@ast
Ching-Hon Pui
@en
Ching-Hon Pui
@nl
type
label
Ching-Hon Pui
@ast
Ching-Hon Pui
@en
Ching-Hon Pui
@nl
prefLabel
Ching-Hon Pui
@ast
Ching-Hon Pui
@en
Ching-Hon Pui
@nl
P1006
P214
P244
P1006
P213
0000 0000 3800 7014
P214
P244
P31
P6023
P7859
lccn-n98802895